PharmiWeb.com - Global Pharma News & Resources

PhagoMed

Research & Development

The company is the brainchild of three very different individuals, who share a common belief: Phage-based drugs are humanities best bet for developing the next generation of anti-bacterials. After working with both engineered phages and synthetic lysins, the company focused on its synthetic lysin platform, the LysinBuilder in 2020.